Baidu
map

J Watch:细胞色素P450效应预测药物相互作用现实吗?

2015-03-02 小吴 编译 医学论坛网

正如在这项氟西汀研究中观察到的,药物代谢比对单个细胞色素P450酶的单一效应复杂得多。 已知氟西汀既是细胞色素P(CYP)450 2D6的底物又是其抑制剂,这导致了旨在预测其在不同2D6基因型患者中的作用以及与其他2D6底物相互作用的尝试。研究人员对了解这种酶是否足够预测临床相互作用进行了调查。 在体外,氟西汀和它的主要活性代谢物诺氟西汀都是2D6、2C19和3A4的

正如在这项氟西汀研究中观察到的,药物代谢比对单个细胞色素P450酶的单一效应复杂得多。

已知氟西汀既是细胞色素P(CYP)450 2D6的底物又是其抑制剂,这导致了旨在预测其在不同2D6基因型患者中的作用以及与其他2D6底物相互作用的尝试。研究人员对了解这种酶是否足够预测临床相互作用进行了调查。

在体外,氟西汀和它的主要活性代谢物诺氟西汀都是2D6、2C19和3A4的强抑制剂。在体内,给10名正常被试12到14天的氟西汀显著减少了2D6底物右美沙芬以及2C19底物奥美拉唑的清除(但没有改变其消除半衰期)。3A4底物咪达唑仑的清除和半衰期没有改变,因为氟西汀和其代谢产物在抑制实际的酶的同时也减少了3A4的信使RNA。母体药物的立体异构体和其代谢产物对CYP450酶有不同的作用。

评论

当前用于预测常用抗精神病药物CYP450相互作用的模型主要基于已知的对单个酶或预期有多个作用时的效应,它们被假设只在一个方向发生。这项研究显示,解释一种代谢产物对所有可能的酶(包括影响不同方向的酶)的影响,以及药物与其立体异构体和代谢产物之间不同的效应很有必要。当药物转运蛋白的效应被考虑进来时,预测各种药物的代谢和相互作用变得更加复杂。临床关键信息:临床医生应在任何药物开始后密切观察患者,而不是仅仅依赖于已发布的或那些由商业基因分型预测的作用。

原始出处:

Do Cytochrome P450 Effects Predict Drug Interactions in Real Life?


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=49350, encodeId=f371493508a, content=新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665377, encodeId=5d8116653e71d, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Fri May 01 10:33:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680272, encodeId=415b16802e2d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 07 07:33:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909179, encodeId=85fd19091e976, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Feb 06 11:33:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471506, encodeId=be0f14e15062c, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585011, encodeId=0a4a15850117a, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602688, encodeId=8c4c1602688e3, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    新知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=49350, encodeId=f371493508a, content=新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665377, encodeId=5d8116653e71d, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Fri May 01 10:33:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680272, encodeId=415b16802e2d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 07 07:33:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909179, encodeId=85fd19091e976, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Feb 06 11:33:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471506, encodeId=be0f14e15062c, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585011, encodeId=0a4a15850117a, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602688, encodeId=8c4c1602688e3, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=49350, encodeId=f371493508a, content=新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665377, encodeId=5d8116653e71d, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Fri May 01 10:33:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680272, encodeId=415b16802e2d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 07 07:33:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909179, encodeId=85fd19091e976, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Feb 06 11:33:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471506, encodeId=be0f14e15062c, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585011, encodeId=0a4a15850117a, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602688, encodeId=8c4c1602688e3, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-11-07 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=49350, encodeId=f371493508a, content=新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665377, encodeId=5d8116653e71d, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Fri May 01 10:33:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680272, encodeId=415b16802e2d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 07 07:33:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909179, encodeId=85fd19091e976, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Feb 06 11:33:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471506, encodeId=be0f14e15062c, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585011, encodeId=0a4a15850117a, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602688, encodeId=8c4c1602688e3, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=49350, encodeId=f371493508a, content=新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665377, encodeId=5d8116653e71d, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Fri May 01 10:33:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680272, encodeId=415b16802e2d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 07 07:33:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909179, encodeId=85fd19091e976, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Feb 06 11:33:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471506, encodeId=be0f14e15062c, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585011, encodeId=0a4a15850117a, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602688, encodeId=8c4c1602688e3, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-03-04 ylz8405
  6. [GetPortalCommentsPageByObjectIdResponse(id=49350, encodeId=f371493508a, content=新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665377, encodeId=5d8116653e71d, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Fri May 01 10:33:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680272, encodeId=415b16802e2d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 07 07:33:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909179, encodeId=85fd19091e976, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Feb 06 11:33:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471506, encodeId=be0f14e15062c, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585011, encodeId=0a4a15850117a, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602688, encodeId=8c4c1602688e3, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=49350, encodeId=f371493508a, content=新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 12:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665377, encodeId=5d8116653e71d, content=<a href='/topic/show?id=fa34186160f' target=_blank style='color:#2F92EE;'>#WATCH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18616, encryptionId=fa34186160f, topicName=WATCH)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=733225951412, createdName=minhuang75_72521592, createdTime=Fri May 01 10:33:00 CST 2015, time=2015-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680272, encodeId=415b16802e2d8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Nov 07 07:33:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909179, encodeId=85fd19091e976, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Feb 06 11:33:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471506, encodeId=be0f14e15062c, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585011, encodeId=0a4a15850117a, content=<a href='/topic/show?id=61888e8231b' target=_blank style='color:#2F92EE;'>#药物相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87823, encryptionId=61888e8231b, topicName=药物相互作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d4517099766, createdName=liao1625, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602688, encodeId=8c4c1602688e3, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Mar 04 00:33:00 CST 2015, time=2015-03-04, status=1, ipAttribution=)]
    2015-03-04 bsmagic9138
Baidu
map
Baidu
map
Baidu
map